In lung adenocarcinoma, E2F1 is downregulated by ATO leading to increased activation of caspase 3 and Bid, and downstream disruption of the cell cycle stages G1 to S phases which are modulated by E2F transcription factor 1 (E2F1) [119,120]. This evidence concerns the gene E2F1 and lung adenocarcinoma.